Nikolaos Papadantonakis MD M.Sc, Ph.D
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant professor
Join to View Full Profile
1365 Clifton Rd NEWinship Cancer InstituteAtlanta, GA 30322
Dr. Papadantonakis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nikolaos Papadantonakis is a hematologist in Atlanta, GA and is affiliated with Winship Cancer Institute of Emory University.
He received his medical and graduate degrees from University of Crete Medical School.
He specializes in hematologic oncology with a focus on acute leukemias, myeloproliferative neoplasms and myelodysplastic syndromes.
His interests are in clinical trials and translational research.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2013 - 2016
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 2010 - 2013
University of Crete School of Health SciencesClass of 2005
University of GlasgowB.Sc, Molecular Biology, 1995 - 1999
Certifications & Licensure
GA State Medical License 2019 - 2027
AL State Medical License 2016 - 2019
OH State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.Michael J Hochman, Joshua P Muniz, Nikolaos Papadantonakis
Journal of Personalized Medicine. 2025-01-26 - Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype.Saja Asakrah, Kristin K Deeb, Nikolaos Papadantonakis, George Deeb
Leukemia Research Reports. 2025-01-01 - 1 citationsMeasurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.Linsheng Zhang, George Deeb, Kristin K Deeb, Colin Vale, Deniz Peker Barclift
Cancers. 2024-04-15
Abstracts/Posters
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Nikolaos Papadantonakis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary MyelofibrosisNikolaos Papadantonakis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...Nikolaos Papadantonakis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients wi...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
